Am J Clin Nutr. 2012 Jan 11.
Wasse H, Huang R, Long Q, Singapuri S, Raggi P, Tangpricha V.
Divisions of Nephrology and Cardiology, Emory University, Atlanta, GA.
BACKGROUND: Vitamin D deficiency is highly prevalent among hemodialysis patients, but little data exist in support of an optimal repletion regimen.
OBJECTIVE: The objective was to ascertain the efficacy of weekly very-high-dose cholecalciferol (vitamin D(3)) in correcting vitamin D insufficiency and deficiency in patients with stage 5D chronic kidney disease.
DESIGN: We conducted a prospective, double-blind, randomized controlled pilot study that compared placebo with very high doses of oral cholecalciferol for 3 wk (200,000 IU/wk) in hemodialysis patients. We examined the rate of correction of vitamin D insufficiency or deficiency and the effect of treatment on markers of mineral metabolism and routine laboratory variables.Results: Twenty-seven subjects received placebo, and 25 received cholecalciferol. The majority (94%) of subjects had serum 25-hydroxyvitamin D [25(OH)D] concentrations <30 ng/mL. Study groups were similar with respect to baseline clinical characteristics, with the exception of hemoglobin concentrations, which were lower in the cholecalciferol-treated group (P < 0.04). At follow-up, 90.5% of subjects treated with cholecalciferol achieved serum 25(OH)D concentrations ?30 ng/mL in contrast to 13.6% of the placebo group. There were no significant changes in serum calcium, phosphate, or intact parathyroid hormone during the study.
CONCLUSION: Short-term, high-dose oral cholecalciferol treatment of vitamin D deficiency in hemodialysis patients appears to be effective and with no evidence of toxic effects. This trial was registered at clinicaltrials.gov as NCT00912782.
Effect of cholecalciferol supplementation on inflammation and cellular alloimmunity in hemodialysis patients: data from a randomized controlled pilot trial.
PLoS One. 2014 Oct 8;9(10):e109998. doi: 10.1371/journal.pone.0109998. eCollection 2014.
Li L1, Lin M1, Krassilnikova M1, Ostrow K1, Bader A1, Radbill B1, Uribarri J1, Tokita J1, Leisman S1, Lapsia V1, Albrecht RA2, García-Sastre A3, Branch AD4, Heeger PS5, Mehrotra A1.
Memory T-cells are mediators of transplant injury, and no therapy is known to prevent the development of cross-reactive memory alloimmunity. Activated vitamin D is immunomodulatory, and vitamin D deficiency, common in hemodialysis patients awaiting transplantation, is associated with a heightened alloimmune response. Thus, we tested the hypothesis that vitamin D3 supplementation would prevent alloreactive T-cell memory formation in vitamin D-deficient hemodialysis patients.
METHODS AND FINDINGS:
We performed a 12-month single-center pilot randomized, controlled trial of 50,000 IU/week of cholecalciferol (D3) versus no supplementation in 96 hemodialysis patients with serum 25(OH)D<25 ng/mL, measuring effects on serum 25(OH)D and phenotypic and functional properties of T-cells. Participants were randomized 2:1 to active treatment versus control. D3 supplementation increased serum 25(OH)D at 6 weeks (13.5 11.2 ng/mL to 42.5 [18.5] ng/mL, p<0.001) and for the duration of the study. No episodes of sustained hypercalcemia occurred in either group. Results of IFNγ ELISPOT-based panel of reactive T-cell assays (PRT), quantifying alloreactive memory, demonstrated greater increases in the controls over 1 year compared to the treatment group (delta PRT in treatment 104.8+/-330.8 vs 252.9+/-431.3 in control), but these changes in PRT between groups did not reach statistical significance (p = 0.25).
D3 supplements are safe, effective at treating vitamin D deficiency, and may prevent time-dependent increases in T-cell alloimmunity in hemodialysis patients, but their effects on alloimmunity need to be confirmed in larger studies. These findings support the routine supplementation of vitamin D-deficient transplant candidates on hemodialysis and highlight the need for large-scale prospective studies of vitamin D supplementation in transplant candidates and recipients.
- All items in category Kidney and vitamin D
- Overview Kidney and vitamin D
- 25,0000 IU vitamin D weekly only raised 60 percent on hemodialysis above 30 ng – Nov 2014
- Some form of vitamin D may be the lowest cost treatment for CKD – Spanish Sept 2011
- Clinical Trials for Vitamin D - 2012 Kidney intervention with vitamin D
Study of Vitamin D and Uric Acid Lowering on Kidney and Blood Vessel Function 21/03/2011
Vitamin D and Arterial Function in Patients With Chronic Kidney Disease 27/06/2011
Vitamin D3 Supplementation in Dialysis Patients 09/03/2011
Effect of vitamin D replacement in patients with chronic kidney disease 25/10/2011
Clinical Trial on the Use of 25-OH -D Vitamin in Haemodialysis Patients 13/10/2011
Study of vitamin D therapy to improve heart function and immune response in patients with chronic kidney disease (CKD) 05/04/2011
Does cholecalciferol (vitamin D3) improve patient-level outcomes for people with chronic kidney disease on dialysis 21/02/2011Hemodialysis low vitamin D status was normalized with 28500 IU avg daily – Jan 2012
3169 visitors, last modified 10 Oct, 2015,